SLAM-family Receptors Promote Resolution of ILC2-mediated Inflammation
Overview
Affiliations
Type 2 innate lymphoid cells (ILC2) initiate early allergic inflammation in the lung, but the factors that promote subsequent resolution of type 2 inflammation and prevent prolonged ILC2 activation are not fully known. Here we show that SLAM-family receptors (SFR) play essential roles in this process. We demonstrate dynamic expression of several SFRs on ILC2s during papain-induced type 2 immunity in mice. SFR deficiency exacerbates ILC2-driven eosinophil infiltration in the lung, and results in a significant increase in IL-13 production by ILC2s exclusively in mediastinal lymph nodes (MLN), leading to increased dendritic cell (DC) and TH2 cell numbers. In MLNs, we observe more frequent interaction between ILC2s and bystander T cells, with T cell-expressed SFRs (especially SLAMF3 and SLAMF5) acting as self-ligands to suppress IL-13 production by ILC2s. Mechanistically, homotypic engagement of SFRs at the interface between ILC2s and T cells delivers inhibitory signaling primarily mediated by SHIP-1. This prevents activation of NF-κB, driven by IL-7 and IL-33, two major drivers of ILC2-mediated type 2 immunity. Thus, our study shows that an ILC2-DC-TH2 regulatory axis may promote the resolution of pulmonary type 2 immune responses, and highlights SLAMF3/SLAMF5 as potential therapeutic targets for ameliorating type 2 immunity.
Adaptive immune cells antagonize ILC2 homeostasis via SLAMF3 and SLAMF5.
Wang Y, Li D, Liu Y, Chen S, Dong Z Sci Adv. 2025; 11(2):eadp9894.
PMID: 39792675 PMC: 11721569. DOI: 10.1126/sciadv.adp9894.
He Y, Yang F, Yang L, Yuan H, You Y, Chen Y Nat Commun. 2024; 15(1):9770.
PMID: 39532893 PMC: 11557922. DOI: 10.1038/s41467-024-54174-5.